检索结果-南通市图书馆

Light-mediated CO_(2)-responsiveness of metallopolymer microgels

维普期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

Chinese Chemical Letters 2022年第3期33卷 1445-1449页

作者： Xiaofei Wang Xuezhen Lin huijuan qiu Jianda Xie Zhengyu Lu Yusong Wang Weitai Wu State Key Laboratory for Physical Chemistry of Solid Surfaces Collaborative Innovation Center of Chemistry for Energy MaterialsThe Key Laboratory for Chemical Biology of Fujian Provinceand Department of ChemistryCollege of Chemistry and Chemical EngineeringXiamen UniversityXiamen 361005China School of Materials Science and Engineering Xiamen University of TechnologyXiamen 361024China Hefei National Laboratory for Physical Sciences at the Microscale University of Science and Technology of ChinaHefei 230026China School of Chemistry and Chemical Engineering Ningxia UniversityYinchuan 750021China

Here, we report a finding on light-mediated CO_(2)^(-)responsiveness. It is found on the microgels that are made of side-chain type metallopolymers containing metalla-aromatics. Turbidity and laser light scattering studies on dilute aqueous dispersion of these microgels in dark indicate high CO_(2)^(-)responsivity, but poor reversibility upon N2 purge, which can be improved by exposing to light. This light-mediated CO_(2)^(-)responsiveness can be elucidated by the loss of aromaticity from initial photoexcitation and concurrent formation of a less reactive, antiaromatic excited state of relatively low CO_(2) binding affinity, and by subsequent relief of antiaromaticity that can enhance the CO_(2) removal. The finding is also checked by CO_(2) uptake-release experiments on the microgels, which enables both CO_(2) capture of high capacity and CO_(2) removal of good reversibility under a mild condition, allowing effective and reversible response to dilute CO_(2).

关键词： Stimuli-responsive Metallopolymers Light Dilute CO_(2) Reversible uptake-release

专案护理在冠脉CTA检查前患者准备中的应用效果

在线全文

学校读者我要写书评

暂无评论

中国医药指南 2024年第24期22卷 36-39页

作者：李明蓉谢淼森张凌菱邱惠娟林艺敏林英利厦门医学院附属海沧医院(厦门市第六医院)门诊部厦门361000

目的分析专案护理干预在冠脉CTA检查前患者准备中的应用价值。方法选取2023年1月至2023年12月在我院接受冠脉CTA检查的178例患者,经随机数字表法将其分成两组,对照组与研究组各89例。对照组接受常规护理干预,如认真做好入院宣教工作,对... 详细信息

目的分析专案护理干预在冠脉CTA检查前患者准备中的应用价值。方法选取2023年1月至2023年12月在我院接受冠脉CTA检查的178例患者,经随机数字表法将其分成两组,对照组与研究组各89例。对照组接受常规护理干预,如认真做好入院宣教工作,对其生命体征进行密切观察,对其过敏史进行了解,并指导其做好相关的准备工作;研究组则接受专案护理干预。比较两组的冠脉CTA检查效率、心理状态、图像质量,以及患者总满意度、主动配合度、相关知识知晓情况。结果相比于对照组,研究组检查准备时间、检查时间更短(P<0.05)。相比于护理前,两组护理后的SDS评分、SAS评分均降低(P<0.05);而与对照组护理后相比,研究组SDS评分、SAS评分降幅更加明显(P<0.05)。研究组的图像质量总体合格率以及患者总满意度、主动配合度、相关知识知晓率均高于对照组(P<0.05)。结论在冠脉CTA检查前患者准备中应用专案护理干预不但能重建、提高患者的认知水平,而且能为其提供正确的心理引导,缓解不良情绪,消除疑虑,进而提高检查效率及患者总满意度。

关键词：冠脉CTA 专案护理干预准备应用价值

Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients with advanced gastric cancer: a report of 14 cases

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2013年第1期12卷 30-34页

作者： Zheng Yan Liangping Xia huijuan qiu Ping Chen Bei Zhang VIP Region Sun Yat-sen University Cancer Center

Objective： Albumin-bound paclitaxel （abraxane, ABX） has more favorable efficacy and less toxicity than conventional taxanes. However, the data of ABX in advanced gastric cancer （AGC） treatment is unavailable. The current study was designed to summarize our experience in treating AGC patients with ABX. Methods： The clinical data of patients with AGC who had received at least one cycle of ABX-based chemotherapy in Sun Yat-sen University Cancer Center from January 10th 2010 to May 14th 2012 was retrospectively analyzed. Results： A total of 47 cycles of ABX-containing regimens, with a median of 3 cycles （range： 1-8 cycles）, were administered to 14 patients. Five （35.7%） partial responses and 6 （42.9%） stable diseases were obtained, with a disease control rate （DCR） of 78.6%. The median progression free survival （PFS） and overall survival （OS） were 3.3 and 10.8 months, respectively. Interestingly, patients in the first-line setting achieved a DCR of 100% （8/8）. Neutropenia and thrombocytopenia were the main grade 3/4 adverse events with an incidence of 50% in the whole group. However, only 25% patients （2/8） experienced grade 3 neutropenia when ABX in combination with fluoropyrJmJdines. Conclusion： The activity of ABX-based regimens as first-line therapy for patients with AGC is remarkable, and the toxicity is mild when ABX combined with fluorepyrimidines. Further prospective clinical trials of ABX-based chemotherapy as first-line treatment for AGC are strongly anticipated.

关键词： albumin-bound paclitaxel (abraxane, ABX) gastric cancer efficacy toxicity chemotherapy

Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting:the summary based on publications

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2010年第3期9卷 137-141页

作者： Liangping Xia Yuming Rong Guifang Guo huijuan qiu Feifei Zhou Fang Wang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen Universty Cancer Center Guangzhou 510060 China

Objective： The combination of cetuximab with standard chemotherapy was not widely studied though it was recommended by NCCN 2009 to apply in non-small cell lung cancer （NSCLC） first-line setting. The aim of this study was to summary the efficacy and safety profiles of all the NSCLC patients available in openly published papers treated with above mentioned regimens. Methods： The PubMed database was used to search all the papers on NSCLC associated with cetuximab treatment, and only the clinical trails applied cetuximab combined with doublets cytotoxic chemotherapy in first-line setting till to 30 November 2009 were collected. And the medians and their 95% CI of objective response rate （ORR）, progression free survival （PFS）, overall survival （OS）, and the common adverse events were calculated. Results：（1） Eight papers including 1032 patients were collected, and all cases were at advanced stage. （2） The ratio of male and female patients was 1.6, 50.1% patients were adenocarcinoma and 28.2% patients were squamous cell carcinoma （SCC）, 90.0% patients were PS = 0-1, and 78.2% patients were white ethnic. （3） The disease control rate （DCR）, ORR, PFS, and OS were 65.2% （95% CI： 60.7%-69.7%）, 33.2% （95% CI： 30.3%-36.1%）, 5.0 months （95% CI： 4.7-5.3） and 10.9 months （95% Cl： 9.6-12.2）, respectively. Conclusion： This is the first study to summarize the efficacy and safety profiles of cetuximab combined with chemotherapy in NSCLC first-line setting based on all available patients. The addition of cetuximab caused promising prognosis and acceptable side effects excepting higher incidence of neutropenia, and febrile neutropenia.

关键词： cetuximab non-small cell lung cancer (NSCLC) first-line setting chemotherapy efficacy adverse event

Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer:a report of 6 cases

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2010年第9期9卷 502-506页

作者： Fang Wang Liangping Xia Guifang Guo huijuan qiu Feifei Zhou Bei Zhang Li Zhang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou 510060 China

Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line *** study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line ***:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, *** short-term efficacies and safeties were ***:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole *** were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) *** were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).*** was no treatment-associated death and no cetuximab-associated *** incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with ***:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.

关键词： cetuximab non-small cell lung cancer (NSCLC) efficacy safety non-first line

Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2009年第11期8卷 669-674页

作者： Liangping Xia Guifang Guo Bei Zhang Ruihua Xu huijuan qiu Yuming Rong Feifei Zhou Fang Wang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medicine Sun Yat-sen Universty Cancer Center Guangzhou 510060 China

Objective： Cetuximab is an effective medicine for colorectal cancer bearing wild type Kras. However, few studies of cetuximab on patients with noncolorectal gastrointestinal cancer were available now. The aim of this study was to summarize the efficacy and safety profiles base-on the experiences of 16 patients with noncolorectal gastrointestinal cancer accepted cetuximab-contained regimens treatment. Methods： The clinical data of all patients with noncolorectal gastrointestinal cancer treated by cetuximab combined with chemotherapy and/or radiotherapy from October 1st 2006 to Jun 30th 2009 in Sun Yat-sen University Cancer Center were collected. Results：（1） A total of 16 patients enrolled, including gastric cancer, esophageal carcinoma, pancreatic cancer and cholangiocarcinoma （8, 6, 1 and 1, respectively）. The cetuximab was administered 92 cycles totally with median cycle of 4. （2） PR, SD and PD obtained in 4, 3 and 2 patients respectively in cetuximab ＋ chemotherapy group. The disease control rate, median l-rP and median OS were 77.8% （7/9）, 3.5 months and 3.5 months, respectively. （3） Both of patients in cetuximab ＋ radiotherapy group achieved PR with median TTP of 4 months and 7 months, with median OS of 14 and 28 months, respectively. （4） in evaluable patients, 3 PR obtained in first-line setting, 1 PD and 1 SD achieved in second-line setting, 2 SD and 1 PD appeared in third-line and more than third-line setting. （5） The commonly side effect was neutropenia, however, rash and hypomagnesemia were the common side effects related to cetuximab. Conclusion： Cetuximab-contained regimens show a promising disease control rate, especially in first-line setting, in patients with noncolorectal gastrointestinal cancer, and the side effects both related to cytotoxic agents and related to cetuximab itself is tolerable and manageable. Of course, more phase Ⅲ clinical trails are needed urgently.

关键词： cetuximab noncolorectal gastrointestinal cancer chemotherapy efficacy

The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2011年第11期10卷 621-625页

作者： huijuan qiu Wenzhuo He Guifang Guo Xuxian Chen Fang Wang Feifei Zhou Chenxi Yin Liangping Xia State Key Laboratory of Oncology in South China Sun Yat-sen University Cancer Center Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Tumor Center The Foshan First People＇s Hospital Foshan528000 China

Objective: The aim of this study was to investigate the efficacy and safety profiles of bevacizumab, the commonly used monoclonal antibody and its safety profiles were challenging, based on Chinese cancer patients. Methods: All the papers studied on Chinese cancer patients treated by bevacizumab were found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the bevacizumab related side effects were analyzed too. Results: (1) There were ten original papers contained total 199 patients who were the candidates to analyze the safety profiles, and 115 patients with colorectal cancer in five papers who were candidates to analyze the efficacy. (2) Nine in ten papers set the dose of bevacizumab in 2.5 mg/kg/week - 5 mg/kg/week, and the biweekly was the standard chemotherapy interval. (3) The disease control rate and response rate in Chinese colorectal cancer patients were 85% (95% CI: 79%-92%) and 61% (95% CI: 52%-70%), respectively. (4) The side effects related to bevacizumab were rare and most of them were grades 1-2, and only one case with grade 4 bleeding was recorded and only two cases with discontinuation of bevacizumab since hemoplysis. Also, the grades 3-4 side effects related cytotoxic agents were not common. Conclusion: This study summarized the data of Chinese cancer patients treated by bevacizumab-contained regimens, and it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients.

关键词： Chinese patient cancer bevacizumab efficacy side effects

Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2014年第5期13卷 229-234页

作者： Ping Chen Bei Zhang Guifang Guo Liangping Xia huijuan qiu State Key Laboratory of Oncology in South China Sun Yat-sen University Cancer Center VIP Region Sun Yat-sen University Cancer Center Collaborative Innovation Center for Cancer Medicine

Objective: The combination of hepatic arterial chemotherapy(HAIC) and systemic chemotherapy(SYC) has potential effect on colorectal cancer(CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metastasis and received combined HAIC and SYC. Among the patients, 23 of them received HAIC plus SYC when they developed liver metastases as first-line treatment(Group 1), and 31 patients received HAIC plus SYC as non-first-line treatment(Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate(ORR) were 52.2% and 25.8% respectively in Groups 1 and 2(P = 0.047), and the disease control rate(DCR) were 65.2% and 35.5% respectively in Groups 1 and 2(P = 0.031). The median progression-free survival(PFS) were 6.8 and 3.3 months(P = 0.002), the median hepatic progression-free survival(H-PFS) were 8.8 and 3.7 months(P = 0.001), and the median overall survival(OS) were 18.8 and 13.7 months(P = 0.121) in Groups 1 and 2, respectively. No fatal reaction was observed and no significant difference of adverse reaction was found in two groups. Grade 3/4 toxic effects included neutropenia(9.7% in Group 2 only), gastrointestinal reaction(8.7% in Group 1 and 6.5% in Group 2), stomatitis(6.5% in Group 2 only) and hyperbilirubinemia(4.3% in Group 1 only). Conclusion: HAIC combined with SYC showed promising efficacy and safe profiles on CRC patients with unresectable liver metastases.

关键词： colorectal cancer (CRC) unresectable hepatic metastasis systemic chemotherapy (SYC) hepatic arterial che-motherapy (HAIC)

The pooled analysis of single gemcitabine for non-small cell lung cancer patients with elderly age

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2010年第12期9卷 683-687页

作者： Fang Wang Liangping Xia Guifang Guo huijuan qiu Feifei Zhou Wenzhuo He State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen Universty Cancer Center Guangzhou 510060 China Tumor Center The First People＇s Hospital of Foshan Foshan 528000 China

Objective:Gemcitabine,used as single agent for elderly patients with non-small cell lung cancer (NSCLC),was demonstrated effective in this population based on phase II *** aim of this study was to summarize all those phase II studies with the hope to get a comprehensive understanding of gemcitabine ***:The PubMed database was used to search all the papers on NSCLC associated with gemcitabine used as single agent in the first line setting till to March 31st,*** the medians and their 95% CI of overall response rate (ORR),disease control rate (DCR),progression free survival (PFS),and overall survival (OS) were ***:*** were 7 papers including 410 patients with performance status (PS) ≤ 2 and advanced stage *** dose-intensities of gemcitabine were 843.75 mg/m 2 /week-1125 mg/m 2 /week in the 4-week schedule,and 666.7 mg/m 2 /week in the 3-week *** median age was 73.8 (95% CI was 72.44,75.16) years old;36.1% (95% CI:31.4%,40.7%) of patients with stage IIIB and 60.5% (95% CI:55.8%,65.2%) of patients with stage IV;35.9% (95% CI:31.2%,40.5%) patients were adenocarcinomas and 43.7% (95% CI:38.9%,48.5%) patients were squamous cell carcinomas (SCCs).*** ORR,DCR,PFS/TTP,and OS were 22.3% (95% CI:18.2%,26.5%),58.4% (95% CI:53.5%,63.4%),3.6 (95% CI:2.9,5.15) months and 6.68 (95% CI:5.4,8.11) months,***:Gemcitabine as single agent applied in this special population was effective and can be well tolerated under different doses and usage.

关键词： elderly non-small cell lung cancer (NSCLC) pooled-analysis gemcitabine first line setting